Plans for the 28th Conference on Retroviruses and Opportunistic Infections (CROI 2021) are currently in development as the COVID-19 pandemic continues to evolve. Abstract categories may be modified from year to year. Please check back later for information abstract categories for CROI 2021.
Notes on Category Selection
Before selecting a category, please consider the following:
- All studies of infants, children, or adolescents should be submitted to Category (P) Pediatrics and Adolescents
- All resistance studies and trials should be submitted to category (I) HIV Drug Resistance
- All studies of Hepatitis (including A, B, C, and E in monoinfection or HIV coinfection) should be submitted to category (J) Hepatitis Viruses and Liver Complications
- Diagnostics: Studies of new technologies related to HIV drug resistance, complications, tuberculosis, other opportunistic infections, hepatitis, or malignancies should be submitted to those specific categories. Studies applying new HIV diagnostics in populations should be submitted to category (R) Testing
- Population and Cost Modeling: Studies that include research on demography, population impact, modeling, and cost-effectiveness should be submitted to the relevant topical category. Reviewers of these abstracts will include individuals with modeling expertise
Studies of viral and host factors, including studies of replication in vitro, host restriction factors, viral life cycle, entry, tropism, and early and late viral phenotypes
Studies of factors influencing disease outcome in humans and animal models, including HIV-host interactions, immune activation, host cell targets, cell compartments, genotype (viral and host) and disease, immune restoration, and mucosal factors
Studies on basic science relating to HIV-associated tumor viruses (eg, KSHV, EBV, HPV, hepatitis B, Merkel cell polyoma virus) including viral life cycle, viral replication and transcription, viral-host interactions, pathogenesis and oncogenesis, and viral immunology
Studies of B- and T-cell responses to viral infection, vaccines, and immune modulation (eg, cytokine interventions)
Studies of all aspects, including human and animal studies, related to these topics
Studies of all aspects of neuropathogenesis, including neuroimmunity, neurodegeneration, virology of the CNS compartment (HIV entry, tropism, evolution, reservoir), CNS complications of systemic HIV infection including neurocognitive dysfunction, and associated factors or responses, cerebrovascular complications (in conjunction with the Cardiovascular Complications clinical group), and biomarkers (including neuroimaging)
All studies of the pharmacokinetics and pharmacodynamics (PK/PD) in animal models and humans, including studies of drug absorption, distribution, metabolism, and excretion, novel dosing regimens, drug interactions, and experimental and clinical therapeutics. Includes pharmacokinetic modeling and simulation studies.
Studies of antiretroviral agents and combinations (all phases, including pre-clinical data), including new agents, combinations, randomized trials and observational and cohort studies where the focus is on antiretroviral therapy and antiretroviral treatment strategies
Studies of molecular mechanisms, pathogenesis, clinical implications, epidemiology, and resistance diagnostics
Studies of diagnostics, epidemiology, pathogenesis, and therapy for hepatitis viruses and liver complications
Studies on the epidemiology, pathobiology, prognostic biomarkers, incidence, treatment, gynecologic malignancies, HPV screening, and prevention approaches for malignancies or premalignant lesions in patients with HIV infection
Includes coronary, cardiac, and cerebrovascular complications, lipids, and peripheral vascular atheromatous disease
Studies of renal, bone, metabolic, and other complications (excluding neurologic or liver complications). Neurologic complications should go to category (E) Neuropathogenesis and CNS HIV Complications and liver complications should go to (K) Hepatitis Viruses and Liver Complications
Basic and clinical examination of bacterial, fungal, parasitic, and non-hepatitis viral infections
Studies of maternal-fetal transmission (including mechanisms), use of antiretrovirals for prevention and treatment during pregnancy and breast feeding, possible risks associated with antiretrovirals in pregnancy and breastfeeding, and early infant diagnosis
Studies of the diagnosis, treatment and management of HIV and related co-infections and co-morbidities in infants, children and adolescents including HIV-exposed uninfected children.
Risk factors for acquisition or transmission, cohort studies, incidence and prevalence, morbidity and mortality, surveillance, transmission clusters, phylogenetics, and molecular epidemiology
Studies applying new HIV diagnostics in populations (eg community-, partner-, and self-testing). Includes studies evaluating tests (such as incidence algorithms), new testing approaches, scale-up of HIV testing, and descriptive epidemiology of testing results.
Preclinical and clinical studies of microbicides, pre- and post-exposure prophylaxis, treatment as prevention, medical male circumcision, and other prevention interventions. Implementation of prevention strategies for HIV uninfected populations, and studies in which HIV incidence is the primary outcome
Studies of: the impact of contraceptive methods on HIV infection or disease; sexually transmitted infections; other aspects of sexual and reproductive health in HIV-infected or at-risk populations. Does not include studies on HIV epidemiology, prevention, and treatment for women; these should be included in their respective categories.
Including cascades of care and treatment, implementation science studies, experiences with scale-up of care and treatment, population-level impact of treatment and care on health outcomes of persons living with HIV, and financing of treatment